Wolf Group Capital Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Wolf Group Capital Advisors’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$351K	Buy	17,111 +2,515	+17%	+$56.1K	0.12%	119
2024 Q4	$341K	Hold	14,596	–	–	0.17%	92
2024 Q3	$341K	Sell	14,596 -2,863	-16%	-$69.8K	0.16%	93
2024 Q2	$404K	Buy	17,459 +2,863	+20%	+$67K	0.16%	95
2024 Q1	$341K	Hold	14,596	–	–	0.16%	93
2023 Q4	$341K	Sell	14,596 -233	-2%	-$4.68K	0.16%	94
2023 Q3	$302K	Buy	14,829 +233	+2%	+$5.23K	0.14%	98
2023 Q2	$351K	Hold	14,596	–	–	0.18%	93
2023 Q1	$340K	Sell	14,596 -650	-4%	-$16.3K	0.17%	92
2022 Q4	$384K	Buy	+15,246	New	+$410K	0.18%	93
2022 Q2	–	Sell	-18,992	Closed	-$654K	–	111
2022 Q1	$654K	Sell	18,992 -31,423	-62%	-$1.11M	0.33%	72
2021 Q4	$2.21M	Buy	50,415 +34,117	+209%	+$1.61M	0.36%	71
2021 Q3	$826K	Sell	16,298 -491	-3%	-$25.6K	0.45%	67
2021 Q2	$874K	Buy	16,789 +7,520	+81%	+$353K	0.47%	64
2021 Q1	$424K	Buy	+9,269	New	+$453K	0.24%	76

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

CCA

Cora Capital Advisors Marlton, New Jersey $356M AUM 27.17% 1-Year Est. Return

Wolf Group Capital Advisors's IDNA Position: Q1 2025 in Review

Wolf Group Capital Advisors increased its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 17% in Q1 2025, buying an estimated $56.1K and bringing the position to 17,111 shares worth $351K. The position accounts for 0.12% of the portfolio, ranked #119.

Wolf Group Capital Advisors first reported a position in IDNA in Q1 2021 and has held it in 15 quarters since. The position peaked at $2.21M in Q4 2021. 48 funds tracked by Wall St. Rank hold IDNA as of Q1 2025.

Wolf Group Capital Advisors held 17,111 shares of iShares Genomics Immunology and Healthcare ETF worth $351K as of Q1 2025.
Wolf Group Capital Advisors bought 2,515 iShares Genomics Immunology and Healthcare ETF shares in Q1 2025, an estimated $56.1K.
iShares Genomics Immunology and Healthcare ETF made up 0.12% of Wolf Group Capital Advisors's portfolio in Q1 2025, its #119 holding.
Wolf Group Capital Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2021 and has held it in 15 quarters since.
Wolf Group Capital Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $2.21M in Q4 2021.
48 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2025.

Based on Wolf Group Capital Advisors's 13F filing for Q1 2025, filed 18 Apr 2025.